down arrow

FibroBiologics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US31573L1052
USD
0.39
0.05 (13.0%)

Dec 12

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.360.41

52 Week

0.242.51
Valuation
Technical
Day's Volume

CASH

206.28 k

Shareholding (Mar 2025)

FII

0.64%

Held by 11 FIIs

DII

90.22%

Held by 10 DIIs

Promoter

0.00%

How big is FibroBiologics, Inc.?

22-Jun-2025

As of Jun 18, FibroBiologics, Inc. has a market capitalization of 28.82 million and reported net sales of 0.00 million with a net profit of -7.67 million over the last four quarters. The balance sheet shows shareholder's funds of 2.73 million and total assets of 22.12 million.

As of Jun 18, FibroBiologics, Inc. has a market capitalization of 28.82 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -7.67 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 2.73 million and total assets amounting to 22.12 million.

Read More

What does FibroBiologics, Inc. do?

22-Jun-2025

FibroBiologics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $28.82 million. The company has no dividend yield and significant negative financial metrics.

Overview:<BR>FibroBiologics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 28.82 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.03<BR>- Return on Equity: -999,999.00%<BR>- Price to Book: 12.27<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is FibroBiologics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, FibroBiologics, Inc. shows a mildly bearish trend with mixed technical signals, significantly underperforming the S&P 500 with year-to-date returns of -73.25% compared to 12.22%.

As of 25 August 2025, the technical trend for FibroBiologics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages are bearish, indicating mixed signals. The RSI shows no signal on both weekly and monthly time frames, and the KST is mildly bullish on a weekly basis. However, Dow Theory remains bearish for both weekly and monthly periods, and the OBV is mildly bearish. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -73.25% versus the S&P 500's 12.22%, and a one-year return of -83.49% compared to 17.14% for the index. Overall, the current stance is mildly bearish with weak indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 24 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.15

stock-summary
Return on Equity

-999,999.00%

stock-summary
Price to Book

23.85

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.62%
0%
-27.62%
6 Months
-54.97%
0%
-54.97%
1 Year
-82.69%
0%
-82.69%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

FibroBiologics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is FibroBiologics, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for FibroBiologics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages are bearish, indicating mixed signals. The RSI shows no signal on both weekly and monthly time frames, and the KST is mildly bullish on a weekly basis. However, Dow Theory remains bearish for both weekly and monthly periods, and the OBV is mildly bearish. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -73.25% versus the S&P 500's 12.22%, and a one-year return of -83.49% compared to 17.14% for the index. Overall, the current stance is mildly bearish with weak indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-54.56%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
15.57
EV to EBIT
-2.49
EV to EBITDA
-2.60
EV to Capital Employed
-34.16
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-728.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 12 Schemes (9.15%)

Foreign Institutions

Held by 11 Foreign Institutions (0.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by FibroBiologics, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.12% vs -223.53% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.20",
          "val2": "-8.50",
          "chgp": "-55.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "6.00",
          "val2": "-7.20",
          "chgp": "183.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-16.50",
          "chgp": "32.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-13.20
-8.50
-55.29%
Interest
0.00
0.10
-100.00%
Exceptional Items
6.00
-7.20
183.33%
Consolidate Net Profit
-11.20
-16.50
32.12%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 32.12% vs -223.53% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About FibroBiologics, Inc. stock-summary
stock-summary
FibroBiologics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."